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Abstract: Neuregulin, a paracrine factor in myocytes, promotes cardiac development via 
the ErbB receptors. Neuregulin-1β also improves cardiac function and cell survival after 
myocardial infarction, although the molecular mechanisms underlying these cardio-
protective effects are not well elucidated. Increased glucose uptake has been shown to be 
cardio-protective during myocardial infarction. Therefore, we hypothesized that acute 
treatment with neuregulin-1β3 isoform, glial growth factor 2 (GGF2; USAN - 
cimaglermin alfa), will enhance glucose transport in the myocardium through insulin and 
calcium-dependent pathways. Isolated cardiac myocytes from healthy adult rats were 
incubated for 1 hour with and without Afatinib, an ErbB 2/4 receptor blocker, and/or 
GGF2 for an additional hour (n=4-15/group). Glucose uptake was measured using a 
fluorescent D-glucose analog. The translocation of the glucose transporter (GLUT) 4 to 
the cell surface, the rate-limiting step in glucose uptake, was measured using a 
photolabeled biotinylation assay. Expression and phosphorylation of key proteins of the 
downstream insulin signaling pathway were measured by Western blotting. Similar to 
insulin, acute GGF2 treatment increased glucose uptake in healthy myocytes (by 49%, 
P<0.05). GGF2 and calcium also increased GLUT4 translocation in myocytes by 117% 
(P<0.02) and 511% (P<0.001), respectively; while ErbB 2/4 blockage blunted these 
effects. GGF2 also enhanced Akt phosphorylation (at both threonine and serine sites, by 
75% and 139%, respectively, P<0.05), which was blunted by ErbB 2/4 blockage. In 
addition, GGF2 treatment increased the phosphorylation of AS160 (an Akt effector) by 
72% (P<0.05), as well as the phosphorylation of PDK-1 and PKC (by 206% and 100%, 
respectively, P<0.05). In conclusion, our data demonstrate that acute GGF2 treatment 
increases GLUT4 translocation and thus glucose uptake, in cardiac myocytes by 
activating the ErbB 2/4 receptors and subsequently key insulin downstream effectors (i.e., 
PDK1, Akt, AS160 and PKC). Similarly, calcium-activated GLUT4 translocation is 
mediated by ErbB 2/4 receptor activation. These findings highlighted some novel 
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Neuregulins (NRGs) are signaling proteins that facilitate cell-cell interactions in the 
nervous system, heart, breast, and other organ systems (7, 8). Neuregulin (NRG)-1β, via 
its ErbB2 and ErbB4 receptors, is crucial for preservation of adult heart function. 
Although the inhibition of ErbB2 has been shown to significantly improve the overall 
survival of breast cancer patients, patients also develop side effects of cardiotoxicity, 
including left ventricular dysfunction and heart failure. This cardiac phenotype observed 
in ErbB2 inhibition elucidates the essential role of ErbB2, ErbB4, and NRG-1β in cardiac 
maintenance of the physiological function of an adult heart (9). Observations of NRG-
1β’s role in cell proliferation, differentiation, and survival have established its role as a 
therapeutic target for heart failure. Animal studies and ongoing clinical trials have 
demonstrated the beneficial effects of two forms of recombinant NRG-1β on cardiac 
function (10-13). Recombinant NRG-1β (rhNRG-1) has been evaluated as a potential 
therapy in many animal models of heart injury, including myocardial infarction, 
ischemia/reperfusion injury, diabetic cardiomyopathy, myocarditis, and chronic rapid 
pacing (14). Glial growth factor 2 (GGF2) is a full-length splice variant of the 
neuregulin-1 gene. In addition to the C-terminal EGF-like receptor binding domain, it 
2 
 
contains an N-terminal Ig-like domain with one or more heparin-binding sites and the 
isoform-specific Kringle domain (15). While it is known that the EGF-like domain is 
sufficient to bind and signal via an ErbB receptor network, it has been demonstrated that 
a single intravenous dose of GGF2 has parallel efficacy to the EGF-domain only 
fragment of rhNRG-1 which was given as daily intravenous infusions over 10 days (11, 
12). In addition, GGF2 administered in patients with symptomatic heart failure improved 
ejection fraction at day 28 and day 90 (11, 12). Yet, the underlying mechanisms 
described in clinical and animal studies by which NRG-1β provides a cardioprotective 
function in vitro as well as its function enhancing property in vivo remain incompletely 
understood. 
As the energetic demands of the heart are extreme (to sustain constant pumping), the 
heart has the highest rate of oxygen consumption per gram of any tissue in the body (16). 
Glucose is a primary energy substrate for the heart, which contributes to 30% of the 
heart’s overall energy through glucose oxidation (16, 17). Even with its ability to utilize 
other substrates such as fatty acids, lactate, ketone bodies, and amino acids, the heart 
must utilize more glucose than skeletal muscle, lung, or adipose tissue in order to 
maintain homeostasis (18, 19). Therefore, glucose uptake is crucial to healthy cardiac 
function. Furthermore, there is a decrease in glucose uptake reported during myocardial 
infarction (MI), as early as 48 hours and up to 10 weeks post-infarction (20-22). 
The translocation of the glucose transporter 4 (GLUT4), the major GLUT isoform, from 
an intracellular pool to the cell surface (active site) is the rate limiting step in glucose 
uptake, and is independently stimulated by insulin- and Ca 2+/ contraction- dependent 
processes (23). Interestingly, it has been reported that neuregulin stimulates glucose 
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transport in skeletal muscle cells via a PI3K-dependent pathway, activating known 
downstream effectors such as PI3K, PDK1, and PKC-ζ (24). Previous studies provide 
evidence that neuregulin’s ErbB receptors during contraction are necessary for 
stimulation of glucose transport and a key component of energetic metabolism during 
muscle contraction. Furthermore, blockage of ErbB4 abruptly impairs contraction-
induced glucose uptake in both slow and fast twitch muscle fibers. Therefore, evidence 
suggests that contraction-induced activation of neuregulin receptors is necessary for the 
stimulation of glucose transport and a key element of energetics during muscle 
contraction (24, 25). Yet, whether neuregulin has similar metabolic effects in the heart is 
unknown. Though the EGF-like domain alone is adequate to activate downstream ErbB 
signaling, the increased efficacy of a single IV dose GGF2 is more clinically appealing 
compared to a 10 day IV treatment with the EGF-domain of rhNRG-1. Therefore, we 
hypothesize that Glial growth factor 2 (GGF2; USAN -cimaglermin alfa) will increase 






REVIEW OF LITERATURE 
 
2.1 Neuregulin-1β (Nrg-1)  
Neuregulins (NRGs) are 
signaling proteins that facilitate 
cell-cell interactions in the 
nervous system, heart, breast, 
and other organ systems (7, 8). 
The NRG-1 gene is located on 
human chromosome 8 and is 
approximately 1.4 megabases 
long, of these, only 0.3% of this 
gene encodes protein (Figure 1, 
(3)). Alternative splicing and 
multiple promoters yield at least 
15 different NRG isoforms are 
produced from the single NRG1  
Figure 1: Human NRG1 gene structure 
(Genbank accession no. BK000383). The NRG1 
gene is on the short arm of chromosome 8. On the 
expanded illustration of this region, the position of 
each exon included in reported NRG1 isoforms is 
indicated by a vertical line. Lines descending 
along the edge of the green box delineate the 
boundaries of the core at-risk haplotype for 
schizophrenia. Only the exon encoding the type II-
specific N-terminal region lies within these 
bounds. Exon naming: Exons are named here for 
the structural region of the NRG1 protein they 
encode. Abbreviations used closely correspond to 
names of NRG protein structural regions indicated 
in panel B. EGFc refers to the exon encoding the 
portion of the EGF-like domain sequence shared 
by NRGs with an -type and NRGs with a -type 
EGF-like domain. The exon labeled TMc also 
includes adjacent extracellular juxtamembrane 
sequence and cytoplasmic tail sequence (3).  
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gene which begets multiple splice variants that can be divided into 3 types of isoforms 
(15, 26). Three structural characteristics that differentiate NRG isoforms with respect to 
in vivo functions and cell biological 
properties are the type of EGF-like 
domain (α or β), the N -terminal 
sequence (type I, II, or III), and 
whether the isoform is initially 
synthesized as a transmembrane or 
nonmembrane protein (Figure 2, 
modified from (5)). Furthermore, 
type I and II NRGs are characterized 
by an immunoglobulin-like domain 
and are single-pass transmembrane 
proteins while type III NRGs possess 
a cysteine-rich domain and are 
additionally characterized as 2-pass 
transmembrane proteins (7). These 
isoforms known as NDF (NEU differentiation factor (27)), heregulin (28), GGF (glial 
growth factor; (29)), ARIA (acetylcholine receptor inducing activity; (30)) or SMDF 
(sensory and motor neuron-derived factor; (31)) vary significantly in their size, structure, 
and tissue specificity. Soluble forms of the NRGs are produced by proteolytic processing 
in the juxtamembrane region of transmembrane precursors where proteolysis can take 
place either within the rough endoplasmic reticulum or at the cell membrane (32). The 
Figure 2: Illustration of NRG “coding 
segments.” Isoforms differ in their coding 
segment composition due to initiation of 
transcription from different NRG1 gene 
promoters and alternative splicing. The EGF-
like domain alone is sufficient for high potency 
activation of the cognate ErbB receptor 
tyrosine kinases. Not all potential 




production of an NRG bioactive fragment is credited to the proteolytic cleavage of type I 
and II neuregulin by participants of the -disintegrin and metalloprotease (ADAM) 
family; including ADAM17 and ADAM19 (33, 34). Neuregulin type III cleavage creates 
a transmembrane N-terminal fragment (NTF) that accumulates at the cell surface. 
Another cleavage of the NTF in the type III NRGs near the membrane can release a 
fragment containing the EGF-like domain into the medium (35).  Only a single domain of 
the NRG precursor, the EGF-like domain, has its bioactivity and importance fully 
appreciated. The EGF-like domain is so called due to its clear structural homology to the 
six-cysteine (joined in three disulfide bonds) bioactive moiety of EGF (36). All NRG 
isoforms that contain the EGF-like domain, including those that are transmembrane 
proteins, undergo alternative splicing, which yields α or β variants. Of the two variants, 
the β variant is considered to be the more active of the two, and it is reported that, when 
compared to the α, the β isoform is up to 100 times more active (7). The EGF-like 
domain contained in all bioactive NRG isoforms is alone sufficient for activation of ErbB 
receptor-tyrosine kinases (15). The stimulation of cell division or the induction of 
differentiation-specific genes are the known functions of the EGF-like domain alone (28, 
36). As a member of the epidermal growth factor (EGF) family, NRG-1 has been 
reported both in vitro and in vivo of many cell types such as breast epithelial, glial, 
neurons, and myocytes to initiate proliferation, differentiation, and survival. (27-30). 
Intricately regulated by neurohormonal and biomechanical stimuli, NRG-1 is synthesized 
and released by endothelial cells within the myocardium (37). Upon binding to its 
tyrosine kinase receptors (ErbB2, ErbB3, and ErbB4), NRG-1 triggers their 
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phosphorylation and downstream cascades including the mTOR pathway for protein 
synthesis as well as JAK/STAT and RAS/ERK pathways for transcription (38).  
 
2.1.1 NRG/ErbB roles in cardiac development 
Function of the cardiovascular system is critical for embryonic survival and, as a 
consequence, the heart must beat to support circulation even before its morphogenesis is 
complete (39, 40). Both the function of the heart and its morphology influence the other’s 
progress (39, 40). This intricate balance forces hearts into very similar functional designs 
that are conserved among widely divergent organisms. Yet, the developmental pathway 
between the simple cardiac tube and the mature four-chambered organ of mammals is 
rather convoluted (Figure 3, (1, 2)). Simply, I will briefly explain each of the four key 
stages in cardiac morphogenesis by developmental day and major characterizations of 
Figure 3: Four key stages in cardiac morphogenesis—tube, loop, chamber 
formation, completion of septation with deployment of coronary circulation. Art 
work by Ivan Helekal based on chick heart development studies by Manner14 and 
Sedmera et al. (1, 2) 
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each. The first cardiac contractions are recognized during the straight tube stage 
(Figure 3), approximately ED (embryonic development) 8.5 in the mouse (41) and 22 
days in humans (42). These first heart beats are irregular and do not possess the force 
needed to propel blood through the circulation (43), yet activity advances rapidly to 
establish coordinated and primitive blood circulation throughout the embryo, thus driving 
development by decreasing diffusion distance for nutrients and oxygen. The next stage of 
embryonic cardiac morphogenesis transitions the straight tube to a looped heart (Figure 
3) known as cardiac looping (44), and for some does not end with loop formation, but 
continues by further ‘twisting’ throughout the septation process (45). In homeotherm 
embryos, pumping function of the tubular heart is required from this stage on, ED10.5 in 
mice, for embryonic survival. Therefore, consequences of perturbations such as 
transgenic knockouts resulting in significant cardiac dysmorphogenesis cannot be 
analyzed in these model species (46). Morphological differentiation of myocardium along 
the cardiac tube becomes apparent soon after looping (47), characterized by the 
development of trabeculae, and, soon afterwards, pectinate muscles in the atria. These 
morphological developments are attended by changes in gene expression patterns (48).  
Life without neuregulins is not possible. The expansive literature reveals how ubiquitous 
and necessary NRG signaling appears to be (Table 1, refer to appendix, (7)). NRGs 
function in vivo will be elucidated by describing the phenotypes of the NRG and ErbB 
knockouts. In vivo studies that blunted the expression of NRG-1, ErbB2, or ErbB4 in 
mice led to death in utero. This phenotype resulted from the failure of cardiac 
development of the endocardial cushions and trabeculae (49-51) (Figure 4, (6)). Both 
ErbB2 (50) and ErbB4 (49) KO mice exhibit analogous phenotypes of death at 
9 
 
Figure 4: Role of Nrg-1/ErbB 
signaling during cardiac 
development. Wild type mouse heart 
develops cardiac cushion and 
trabeculae between day 9.5 and day 
10.5 of fetal development. Lack of 
Nrg-1 effectively blocks the 
formations of such structures. Lack of 
ErbB2 leads to impaired formation of 
trabeculae and in some hearts also of 
cardiac cushion. ErbB4 null mice 
specifically display lack of 
trabeculation whereas ErbB3 null 
mice develop normal trabeculae but 
they do not form a normal cardiac 
cushion (6). 
embryonic day 10.5, the time at which mice embryos switch from dependence on 
maternal circulation to dependence on their own circulation. These phenotypes are a 
result of myocyte proliferation resulting in 
the thickening of the ventricular wall from 
lack of trabeculation as well as insufficient 
ability to maintain blood circulation due to 
the development of only a single-cell layer 
of myocytes forming the ventricle. (49, 50). 
Control littermates demonstrated expression 
of ErbB2 and ErbB4 receptors in the 
ventricular trabeculae determined by 
immunohistochemistry (49). Furthermore, 
ErbB2-deficient mice also exhibit failing 
endocardial cushions during fetal heart 
development (50). Similar to ErbB2 
knockouts, mice deficient in NRG-1 acquire 
both trabeculae and endocardial cushion 
defects. Therefore, NRG-1 is required for 
both the development of trabeculae and 
endocardial cushion. Dying between days 
10.5-11.5, NRG-1 null mice are comparable in size and overall embryonic structure to 
wild type, yet histological analysis revealed lack of trabeculation and an unclosed 
endocardial cushion yielding loss of function of the heart (51). The parallel phenotype 
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demonstrated between Nrg-1, ErbB2, and ErbB4 null mice as a requirement for 
ventricular trabeculation lend insight to these proteins’ interactions and dependence on 
each other (6). 
2.1.2 NRG-1/ErbB and cardiac structure and function 
NRG-1 expression (52) alongside ErbB2 and ErbB4 receptors is also expressed in the 
adult heart, although ErbB3 ceases to be expressed (53). It has been reported that NRG-1 
expression is specific to the endocardium and myocardial microvasculature, as it is not 
found in the coronary arteries, veins, or aorta (54). NRG-1/ErbB signaling is adaptive 
under a variety of circumstances through which it plays a role in regulating survival of 
cardiomyocytes (53, 55), angiogenesis (56), excitation-contraction (57), proliferation (53, 
58), cell-to-cell contact between myocytes (59), and preventing oxidative stress induced 
apoptosis (60). Although ErbB2 does not bind NRG-1, it is the preferred heterodimer for 
both ErbB3 and ErbB4 and is necessary for ErbB signaling within the adult heart (61). 
Further reports confirm that not only is ErbB4 actively involved in cell protection (55, 
60), but is also mediated by ErbB2 (54). These findings further validate protein 
interactions between NRG-1 and ErbB receptors described during embryonic cardiac 
development to be true in mediating NRG-1 signaling in the adult heart. Additional 
studies conditionally knocked out ErbB2 and ErbB4 in the post-natal heart (62, 63). I 
immunohistochemistry revealed not only abnormal distribution of the ErbB2 receptor but 
increased viniculin, a cytoskeletal protein associated with cell-cell and cell-matrix 
junctions, at the intercalated disks in ErbB4 knockout mice (62). ErbB2, ErbB4, and 
NRG-1 knockouts developed dilated cardiomyopathy, reduction of fractional shortening, 
and impaired contractility, alongside delayed conduction (62-64). The expression of atrial 
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natriuretic peptide (ANP) and skeletal a-actin genes in ErbB2 knockouts were congruous 
with heart failure development as well as the inability to survive aortic binding-induced 
pressure overload (65). Although the role of NRG-1, ErbB2, and ErbB4 has not been 
completely elucidated, it can be inferred that all are essential in the maintenance of 
ventricular structure and function in the neonatal and adult heart. 
2.2 Pharmacological actions and therapeutic indications 
 2.2.1 Stroke and related neurological diseases 
In 2012, an estimated 6.6 million Americans ≥20 years of age have had a stroke. Overall 
stroke prevalence during this period was an estimated 2.6% (66). Stroke is determined by 
poor blood flow to the brain resulting in cell death. There are two main types of stroke: 
ischemic, due to lack of blood flow, and hemorrhagic, due to bleeding (66). Historically, 
the first suggestion that NRG-1 might have some role in the heart came from studies in 
mice, which were genetically manipulated to remove functional NRG-1 and its receptors 
in order to determine the function of NRG-1 in the nervous system as it applied to stroke 
victims (49, 51). Mice with disrupted NRG-1, ErbB 2, 3 and 4 receptors demonstrated 
both abnormal neural and cardiac development (49, 51). Further studies of the 
neuregulin’s action demonstrated its neuroprotective and neurorestorative properties in 
central and peripheral nervous system models of injury (67, 68). A neuregulin-1 EGF-like 
fragment demonstrated neuroprotection in the transient middle cerebral artery occlusion 
(MCAO) stroke model and drastically reduced infarct volume (69). Furthermore, a 
permanent MCAO rat model was used to compare two products of the neuregulin-1 gene 
as well as assess levels of recovery with acute versus delayed time to treatment (70). This 
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study demonstrated that the GGF2 isoform of NRG-1 had similar functional 
improvements compared to the EGF-like domain fragment at equimolar doses. GGF2 
improved sensorimotor recovery with all treatment paradigms, even enhancing recovery 
of function with a delay of 7 days to treatment. Neurorestorative effects of this kind are 
of great potential clinical importance, given the difficulty of delivering neuroprotective 
therapies within a short time after an ischemic event in human patients (70). 
2.2.2 Cardiovascular diseases 
The Centers for Disease Control estimates that the number of occurrences of myocardial 
infarction (MI) in the US to be 715,000 in 2012, with a survival rate of 50% (71). MI, or 
heart attack, is characterized by the lack of blood flow to the myocardial tissue resulting 
in damage to or necrosis of the cardiac myocytes. According to 
American Heart Association in their 2015 update, coronary artery disease is the leading 
cause of heart attacks (66). Myocardial infarction, which can lead to heart failure (HF), is 
a compounded syndrome that develops over months to years. Heart failure is described as 
the structural, functional, and bioenergetic derangement of the heart, which results in its 
inability to perform the hemodynamic requirements of the body. With the rate of glucose 
utilization being greater in the heart compared to other tissues, altered substrate 
utilization, resulting from decreased glucose uptake and/or oxidation, could underlie 
contractile dysfunction reported in HF (72, 73).  
In a healthy heart, ventricular diastole, the pressure in the (left and right) ventricles, drops 
below the pressure in the left atrium, initiating the opening of the mitral valve allowing 
accumulated blood from the atrium to flow into the ventricle. The ventricular filling 
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velocity or flow into the ventricles can be described by its early and late phase; first an 
early (E) diastolic filling causes ventricular suction, and second, a late filling is created 
by atrial contraction (A). The E/A ratio can be used as a diagnostic measure, since it is 
reduced in diastolic dysfunction (74). Furthermore, when the smaller, upper atria 
chambers contract during late diastole, they force blood into the larger, lower ventricle 
chambers. The lower chambers when filled are accompanied by the closing of the atrial 
valves, initiating the isovolumetric contraction (contraction of the ventricles while all 
valves are closed) of the ventricles, marking the first stage of systole. The second phase 
of systole forces blood from the left ventricle into the aorta to be delivered to body 
extremities, and from the right ventricle to the lungs. Ejection fraction (EF) is, therefore, 
defined as the fraction of outbound blood pumped from the heart with each heartbeat. It is 
commonly measured by echocardiogram and serves as a measurement of a person's 
cardiac function (75, 76). 
Similar to it neurorestorative effects, NRG-1 has been reported to correlate to a certain 
degree with cardiovascular health. Both exercise and injury of skeletal and cardiac 
muscle activates the cleavage and release of NRG-1 in rodent models and is also 
detectable in human circulation (14). In studies that compare the level of circulating 
NRG-1, it was reported that healthy subjects express levels of NRG-1 that correlate with 
cardiopulmonary fitness (77), yet those presenting cardiovascular disease had levels 
associated with cardiac stress. Even further, it has been reported that when non-ischemic 
heart failure was compared to ischemic cardiomyopathy, NRG-1 was significantly higher 
in the circulation of patients with ischemic systolic heart failure. These higher levels were 
also associated with increased risk of cardiac transplantation or death (78). 
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a. Neuregulin-1 in animal studies 
It has also been established that significant changes of the cardiac NRG-1/ErbB system 
occur as chronic heart failure (CHF) progresses in animal models (54, 79, 80). Expression 
of NRG-1/ErbB increases during early stages of CHF and decreases as pump failure 
occurs. During the development of concentric left ventricular hypertrophy, NRG-1 
mRNA levels is reported to increase, potentially as a consequence of mechanical wall 
strain. As eccentric ventricular hypertrophy and pump failure arise, the decline in NRG-1 
expression is combined with the downregulation in mRNA levels of ErbB2 and ErbB4. 
This downregulation of NRG-1 mRNA during heart failure is thought to be associated 
with increased angiotensin II and epinephrine expression, which have been demonstrated 
to reduce NRG-1 mRNA synthesis in cardiac endothelium (54). How the expression of 
NRG-1 and ErbB lead to changes in NRG-1/ErbB signaling and further the remodeling of 
the ventricle is still under investigation. Dr. Lemmons speculates that fluctuations in 
NRG-1 and ErbB mRNA expression in early and late phases of CHF could be adaptive 
for tissue integrity and growth in the early phases, then in response to hemodynamic 
conditions and peripheral circulation during late phases (81). 
Understanding that NRG-1/ErbB signaling exhibits protective effects on the myocardium, 
has led researchers to determine whether NRG-1 activation of ErbB downstream 
signaling has therapeutic benefits in HF. For instance, a short-term intravenous (IV) 
administration of recombinant NRG-1 demonstrated an improvement in cardiac function 
and survival during cardiomyopathy (13). This improvement seems to be additive to 
treatment with angiotensin-converting enzyme inhibitors and is observed even if NRG-1 
treatment began following the onset of cardiomyopathy (13). Therefore, it can be 
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concluded that rhNRG-1β stimulated reverse remodeling, a contrast from simply 
preventing further cardiac remodeling. NRG-1β’s involvement in reverse remodeling is 
evident by its anti-fibrotic effects in animal models of heart failure. For instance, studies 
in rats with diabetic cardiomyopathy demonstrated that myocardial interstitial fibrosis is 
attenuated by NRG-1 (82). Furthermore, reduced fibrosis was reported during 
cardiomyopathy in a large animal model (swine) treated with the GGF2 isoform of NRG‐
1β (83). 
b. Neuregulin-1 treatment in human clinical trials 
There are currently two forms of recombinant NRG-1 in clinical trials. As briefly 
mentioned above, both demonstrate promising benefits for the treatment of heart failure 
in animal models. Similar results have been reported in human clinical trials. Phase II 
clinical trials with rhNRG-1 in which patients with stable chronic heart failure received 
daily intravenous infusions were reported to be safe and well tolerated (10, 84). Utilizing 
a double-blind multicenter study, participants received either NRG-1 or placebo for 10 
days, in addition to standard therapy. Patients with stable chronic heart failure receiving 
rhNRG-1 displayed significantly increased left ventricular ejection fraction and reduced 
end-systolic and -diastolic volumes (75, 76)) at day 30. These improved parameters were 
furthermore present at day 90 (84). From these studies, it can be concluded that NRG-1 
plays a therapeutic role in reversing cardiac remodeling in humans. Fifteen patients in a 
second clinical trial who received daily intravenous infusions of rhNRG-1 for 10 days 
demonstrated improved and sustained hemodynamics (10). Currently larger Phase II 
trials are ongoing, as well as a Phase III trial to measure the effects of rhNRG-1 treatment 
on the death rate of patients presenting with chronic heart failure. 
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A phase I clinical trial in which 40 patients with symptomatic heart failure were given a 
single dose of GGF2 intravenously was generally well tolerated. The completion of this 
study revealed a dose-responsive increase in ejection fraction at day 28 and was 
consistent through day 90 (11, 12). Preliminary data illustrates that this single dose of 
GGF2 has parallel efficacy to the EGF-domain only fragment of rhNRG-1, which was 
given over 10 days. This efficacy has been suggested to be attributable to the additional 
Kringle domain present in GGF2, but not in the rhNRG-1 (11, 12). Exciting, NRG-1 
demonstrates cardioprotective benefits and enhanced contractility in animal and human 
studies, respectively. 
  c. Neuregulin-1 in diabetic cardiomyopathy 
Long et. al. reported that DCM impairs NRG-1/ErbB signaling via a rat model of DCM 
established using a single intraperitoneal injection of streptozotocin (STZ) and confirmed 
by dramatic left ventricle fibrosis and impaired left ventricle systolic function at 12 
weeks STZ-induced diabetes. ErbB2 and ErbB4 mRNA expression and NRG1 protein 
expression in the left ventricular myocardium were significantly decreased. Furthermore, 
this model of DCM demonstrated a decrease in phosphorylation of the ErbB2 and ErbB4 
receptors (85). Interestingly, a study in streptozotocin-induced Type 1 diabetes in rats 
concluded that administration of NRG-1 improved cardiac function and reversed 
remodeling of the heart of DCM rats by attenuating cardiac fibrosis, although the precise 
mechanism was unclear (86). The rhNRG-1 treatment resulted in significantly less 
apoptotic cells than untreated group as determined by the TUNNEL method. 
Furthermore, mRNA expression of bcl-2, bax, and capase-3, which are regarded as the 
markers of apoptosis (bcl-2 is known for anti-apoptosis, and bax and caspase-3 pro-
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apoptosis) revealed  that Type 1 diabetes mice expressed bcl-2 was down regulated but 
bax and capase-3 were up regulated, whereas, rhNRG-1 alleviated the changes. These 
results indicate that rhNRG-1 treatment protects cardiomyocytes against apoptosis during 
DCM (86).  
In a complementative study, human NRG-1 (hNRG-1) lentivirus was transfected into rat 
cardiac microvascular endothelial cells in vitro by conditioned media as well as injected 
into the myocardium of the DCM model rats in vivo (87). hNRG-1 conditioned medium 
initiated proliferation of cardiomyocytes as well as reversed apoptosis. Furthermore, 
DCM rats that received the hNRG-1 gene transfer displayed improved heart function, as 
indicated by invasive hemodynamic measurements (cardiac catheterization to measure 
ventricular pressure) (87). In agreement with the Li lab (86), hNRG-1 reduced the 
number of apoptotic cells, decreased the expression of bax and increased the expression 
of bcl-2 in the myocardium of the DCM model rats (87). Additionally, mRNA levels of 
type I and III pro-collagen as well as myocardial fibrosis were markedly reduced in 
hNRG-1 transfected rats (87). The combinations of results from these studies align to 
conclude that NRG-1 ameliorates cardiac dysfunction in diabetes. 
2.3 Glucose metabolism in striated muscle 
2.3.1 Regulation of glucose metabolism 
Whole-body glucose homeostasis, a delicate balance of glucose anabolism and 
catabolism is maintained by glucose transport in several tissue types. Glucose uptake is 
the rate-limiting step of glucose metabolism and is mediated by a family of specialized 
proteins, called glucose transporters (GLUTs) (88). GLUTs are glycoproteins, 
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approximately 50-60kDa in size, which facilitates glucose uptake from the blood to the 
cells.  The major isoform expressed in myocytes, GLUT4, is translocated from an 
intracellular pool to the cell membrane during insulin-mediated glucose uptake in striated 
muscle. Under basal conditions, GLUT4 is primarily located within multiple intracellular 
compartments such that only 2-5% is reported at the plasma membrane (89-93). Yet, 
other isoforms expressed in insulin-sensitive tissues also participate in glucose uptake, 
including the basally expressed GLUT1 and the novel GLUT8 (94). Glucose uptake is 
mediated by activation of the phosphatidylinositol-3-kinase (PI3K) cascade or by PI3K-
independent pathways mediated by effectors such as AMPK or calcium (95).  
Although the mechanisms of insulin regulation of GLUT4 within cardiac tissue is not 
fully known, recent data suggests that GLUT4 may have roles in the regulation of 
glycolysis even beyond its ability to transport glucose (96). Cardiomyocyte-specific 
GLUT4 knockout mice displayed reduced levels of insulin-responsive aminopeptidase 
(IRAP) known to be related with impaired GLUT4 trafficking (97). Similar to skeletal 
muscle, cardiomyocyte GLUT4-mediated glucose uptake can be activated through a G 
protein, PI3K, and 1,4,5-inositol-triphosphate (IP3) signaling cascade. Interestingly, it 
has been reported that activation of this signaling axis increases propagation of 
cytoplasmic calcium signals, which also initiate GLUT4 translocation (98). Accordingly, 
these data highlight the necessary role of GLUT4 in the insulin-mediated cardiac glucose 
metabolism. Furthermore, heterozygous GLUT4+/- knockout mice displayed increased 
serum glucose and insulin, reduced muscle glucose uptake, and diabetic histopathologies 




2.3.2 PI3K-dependent GLUT4 regulation 
Absorption of glucose causes an increase in blood glucose, which consequently yields a 
rise in pancreatic beta cell release 
of insulin into the blood. Insulin 
binds to its receptor initiating an 
intracellular cascade, which 
results in the translocation of 
insulin-sensitive GLUT4 from 
the cytosol to the plasma 
membrane. The insulin-
dependent or PI3K 
(phosphoinositide-3-kinase) 
pathway and has been extensively 
investigated (Figure 5, artistic 
credit to Dominic Martin). Upon insulin binding to its receptor (insulin receptor, IR), 
autophosphorylation triggers downstream effectors to phosphorylate PI3K and further 
downstream targets (100-103). Studies have characterized the serine/threonine kinases 
downstream of the IR regulating GLUT4 translocation. One of such candidates include 
Akt/protein kinase B, which is activated by its binding to these membrane bound lipids 
via the 3’-polyphosphoinositide-dependent protein kinase PDK1 (104). It has been 
demonstrated in 3T3-L1 adipocytes (105), primary adipocytes (106), and L6 myotubes 
(107) that membrane-directed constructs of Akt/PKB stimulates GLUT4 translocation, a 
mechanism that is blunted by inhibitory constructs (106). In contrast, a dominant 
Figure 5: The downstream insulin signaling 
pathway. The above schematic outlines a portion 
of the downstream insulin-signaling pathway. 
Abbreviations are used as follows: P = 
phosphorylated, PI3K = Phosphoinositide 3-
kinase, PKC = Protein kinase C, Akt2 = Protein 
kinase B isoform 2, AS160 = Akt substrate at 160 
kD, GLUT4 = Glucose transporter isoform 4 
(artistic credit to Dominic Martin). 
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inhibitory mutant Akt/PKB with alanine substitutions within the threonine 308 and serine 
473 phosphorylation sites inhibited protein synthesis but not insulin-stimulated glucose 
transport, as demonstrated in both Chinese hamster ovary cells and 3T3-L1 adipocytes 
(108). These data suggest that Akt-initiated GLUT4 activity is dependent on location 
within the cell compared to activation by its phosphorylation sites. A more in depth 
investigation at the activation of these phosphorylation sites indicated that Akt 
phosphorylation at Th308 site is mediated directly by PDK-1 (109-111), while Akt 
phosphorylation at Ser473 is facilitated by the rictor-mammalian target of rapamycin, 
also known as mTOR-2 (110, 112). During experimental Type 1 diabetes, a lack of 
insulin production is accompanied by baseline decreases in cardiac Akt activity (113). 
Yet, when streptozotocin (STZ)-diabetic rats were given systemic insulin, there was a 
restoration of activity in nearly every protein within the PI3K/Akt signaling cascade 
within the myocardium, including Akt phosphorylation (114). From this, we can 
conclude that the lack of insulin production during insulin-deficient Type 1 diabetes 
induces alteration in PI3K/Akt activation. Conversely, insulin-resistant Type 2 diabetes 
displays diminished insulin action on the PI3K/Akt signaling cascade (115). 
Akt-substrate at 160kD (AS160), is the downstream target of Akt, as its name indicates. 
Upon activation, AS160 actively converts Rab-GDP to Rab-GTP which initiates GLUT4 
vesicles translocation to the cell membrane (116). Karlsson et. al. demonstrated in 2005 
that impairment of insulin action during Type 2 diabetes results in decreased AS160 
phosphorylation at its Th308 site in skeletal muscle, yet there was no change in total 
expression of AS160 (116). Akt impairment was further confirmed in the adipocytes of 
Type 2 diabetic patients as well as rodents as reported by Rodinone et. al. and Carvalho 
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et. al. (117, 118). Furthermore, defective phosphorylation of Akt led to defects in GLUT4 
translocation (119, 120) as observed in Akt knockout mouse models during insulin 
resistance (121). These Akt knockout mice exhibit hyperglycemia, hyperinsulinemia, and 
impaired glucose tolerance. These studies elaborate on the necessary involvement of 
PDK-1, Akt, and AS160 during insulin-dependent GLUT4 translocation and glucose 
uptake. 
In a similar PI3K-dependent Akt-independent mechanism, protein kinase C ζ (PKC-ζ), is 
activated by polyphosphoinositides via insulin in a wortmannin-sensitive manner. Insulin 
stimulates swift increases in PKC-ζ activity in 3T3-L1 adipocytes (122), L6 myotubes 
(123), rat adipocytes (124), and 32D cells (125) via PI3K-dependent stimulation (123-
125). Downstream from PI3K, PDK-1 derives access to the activation of PKC-ζ through 
conformational regulation such that the autoinhibitory pseudosubstrate sequence of PKC-
ζ must be removed in order to reveal the binding cavity for PDK-1 to phosphorylate 
PKC-ζ. This serves as a direct “On/Off” switch for the activity of PKC-ζ (126). It has 
been well established that inhibitors of PKC-ζ concurrently impede insulin effects on 
glucose transport as demonstrated in adipocytes (124) and L6 myotubes (123). To further 
confirm PKC-ζ involvement in insulin-stimulated glucose uptake, a kinase-inactive (KI) 
form of PKC-ζ displayed inhibition of GLUT4 translocation and glucose transport in 
transfected 3T3-L1 cells (122) and L6 myotubes (123). These data suggest that insulin-
dependent not only initiates Akt/AS160 GLUT4 translocation, but the alternative PKC 
pathway is directly involved in GLUT4 translocation. 
2.3.3 PI3K-independent GLUT4 regulation 
22 
 
Investigations of insulin-independent mechanisms lend us insight into the regulation 
GLUT4 translocation during skeletal muscle contraction. It has been observed that 
increases in glucose transport are due to the additive effects of both insulin and 
contraction in striated muscle, yet only insulin-dependent glucose uptake is blocked by 
wortmannin (127). Similar studies have reported that insulin, not contraction, stimulates 
PI3K and Akt activity (128). Hayashi’s lab demonstrated that contraction mediates 5’-
AMP-activated protein kinase’s (AMPK) role in the regulation of cell stress in the rat 
hind limb, yet insulin did not elucidate this response (129). Interestingly, another AMPK 
activator, apart from contraction, mimicked the contraction-induced glucose uptake in a 
wortmannin-insensitive manner (129). 
To further understand these concepts above, I will expand on roles of AMPK, calcium-
calmodulin kinase (CAMK), and calcium-initiated glucose uptake in striated muscle, 
beginning with the former. AMPK, a protein complex composed of 12 molecules 
containing α, β and γ subunits (130, 131). The α-subunit retains catalytic activity while 
the β and γ subunits have important roles in substrate specificity and maintaining stability 
of the heterotrimer (132, 133). AMPK’s role in insulin-independent glucose uptake, 
which is stimulated by the contraction events of skeletal muscle, is crucial in myocytes. 
AMPK activity is activated by the AMP:ATP ratio and further reduced by the 
creatine:phosphocreatine ratio (134-136). Increased AMP levels allosterically activate 
AMPK prompting phosphorylation of Thr172 within the catalytic α-subunit (130, 131, 
137). It is therefore presumed that AMPK activation during contraction is the response to 
increased AMP:ADP binding and decreased ATP to γ-subunit binding (138). 5-
aminoimidazole-4carboxamide-1-ß-D-ribonucleoside (AICAR) mimics the role of AMP 
23 
 
on AMPK as demonstrated during in vitro studies on isolated rat muscles exposed to 
AICAR, which increased glucose transport in the absence of insulin. In conjunction, 
healthy and Type 2 diabetic human muscles treated with AICAR responded in the same 
way (129, 139-141). As expected, there was an additive effect of glucose uptake when 
striated muscle and neuronal cells were treated with combined AICAR and insulin 
simultaneously (142, 143). However, when AMPK α2 or γ3 subunits are deficient, the 
AICAR-induced glucose uptake is blunted (144, 145). Furthermore, glucose uptake is 
induced by two distinct pathways when comparing AICAR and contraction. Mouse 
soleus and EDL muscles having α1 or α2-AMPK knockouts stimulated by muscle 
contraction expressed similar glucose uptake compared to wild-type mice. Interestingly, 
when stimulated with AICAR, only α1-AMPK KO mice displayed consistent glucose 
uptake. These studies conclude that AICAR-stimulated glucose uptake is dependent of 
the α2-AMPK subunit (144). In summary, increased levels of AMP and ADP by 
contraction events seem to be the primary activator of AMPK-stimulated glucose uptake. 
In addition, skeletal muscle contractions can supply increased calcium concentrations 
within the myocytes (133, 146). This increase in calcium concentrations has been 
observed to stimulate glucose uptake and GLUT4 translocation (133, 147). Interestingly, 
it has been reported that calcium alone stimulates glucose uptake independent of 
contraction in skeletal muscle (148), although the mechanisms by which this occurs is not 
well understood. Candidates within the downstream signaling cascade of calcium-
initiated glucose uptake include calmodulin-protein kinase and PKC (134, 138, 149).  
The calcium-calmodulin kinase (CAMK) initiates activations of AMPK via 
phosphorylation of Thr172, in addition to activation of GLUT4 translocation through 
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alternative effectors (132, 150-153). Furthermore, reports of isolated rat muscles treated 
with caffeine stimulates increases in intracellular calcium levels with parallel increases in 
glucose uptake independent of contraction (154). It has been confirmed by several labs 
that caffeine incubation in muscles of both mice and rats increase nucleotide turnover and 
AMPK activation, also independent of contraction (132, 138, 155). It has been proposed 
that this increased nucleotide turnover and AMPK activation is due to the pertinent 
demand of energy by the sarcoplasmic reticulum Ca2+-ATPase-dependent (SERCA) 
Ca2+ reuptake (138, 156). Concluding from these studies, metabolic stress yields 
increased glucose uptake, triggered by SERCA activation and muscle contraction, not the 
direct action of calcium (157). These studies elucidate the essential insulin-dependent and 
–independent activation of GLUT4 mediated glucose uptake. 
2.3.4 The effect of NRG-1 on glucose metabolism in skeletal muscle 
Neuregulins play a central role in muscle biology. They are synthesized by myoblast cells 
and initiate an autocrine signaling pathway that promotes myogenic differentiation (158). 
Interestingly, neuregulin has been demonstrated to increase glucose uptake in skeletal 
muscle, independently of insulin action (159). Sawyer’s lab demonstrated that multiple 
isoforms of NRG and its ErbB2, -3, and -4 receptors were highly expressed in adult 
skeletal muscle which are activated in response to contractile activity. In vivo proteolytic 
processing of NRG with simultaneous activation of these ErbB receptors were initiated 
by two distinct modes of exercise. Interestingly, there was increased expression of ErbB3 
in extensor digitorum longus (EDL) muscles a (predominantly fast-twitch muscle) 
compared to soleus muscle (a predominantly slow-twitch, oxidative muscle) (160). 
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Furthermore, being akin in structure slow-twitch skeletal muscle, adult cardiac myocytes 
do not express ErbB3 (53). 
Dr. Suarez’s lab reported neuregulin’s rapid effects on glucose transport in muscle cells 
independent of changes in gene expression (159). This was elucidated by the increased 
translocation of GLUT1, GLUT3, and GLUT4 upon stimulation by NRG in 
cultured L6E9 cells, and was independent of changes in GLUT gene expression (159). 
Similar to insulin stimulation, NRG treatment induces the translocation of GLUT4 in 
skeletal muscle myocytes. Furthermore, when NRG and insulin treatments were 
combined, the stimulation of GLUT transport was additive. In addition, NRG’s effect on 
glucose transport was blunted by wortmannin, a PI3K inhibitor. These findings suggest a 
PI3K-dependent mechanism for glucose uptake stimulated by NRG (159). 
Dr. Canto and Dr. Suarez also demonstrated in vitro contractions stimulated ErbB4-
mediated glucose uptake, but not ErbB3, in soleus muscle (25). This was secondary to 
their previous finding in which ErbB3 phosphorylation levels were minimal in the 
presence of saturating concentrations of neuregulins in soleus muscle (25). Ex vivo 
blocking of ErbB4 had more dramatic effects on calcium-mediated glucose uptake in 
slow-twitch soleus muscle fibers compared to fast-twitch EDL muscles (24).  
Furthermore, when ErbB4-specific antibodies blocked its phosphorylation in vitro, ErbB3 
receptors were minimally phosphorylated in the presence of caffeine. Even still, caffeine 
did not induce glucose uptake in these circumstances. To validate that ErbB3 was not 
involved in the activation of glucose uptake, ErbB3-specific antibodies blunted its 
phosphorylation but did not impair the stimulation of glucose uptake during any 
conditions tested (25). 
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Dr. Canto further postulated that neuregulins are necessary effectors for calcium 
signaling to induce glucose uptake in skeletal muscle (24). To determine if calcium-
mediated glucose uptake via ErbB4 receptor was dependent upon CAMKII, they 
inhibited CAMKII and reported no effect on ErbB4 phosphorylation, suggesting that 
CAMKII is not involved in calcium-mediated ErbB receptor phosphorylation (24). 
Similarly, to determine if AMPK-induced glucose uptake is independent of neuregulin 
action, they demonstrated that AICAR (5-Aminoimidazole-4-carboxamide 
ribonucleotide, an AMPK activator) does not increase phosphorylation of the ErbB 
receptors, nor does blockage of ErbB4 affect AMPK-stimulated glucose uptake (24). 
Therefore, calcium-mediated neuregulin stimulation increased glucose transport 
independent of AMPK and CAMKII.  
2.3.5 Alterations of glucose metabolism during cardiovascular diseases 
In order to sustain the high rate of contraction, the energetic demand of the heart is 
greater compared to other tissue. Therefore, the heart requires an increased rate of oxygen 
consumption per gram of tissue (16, 17). Glucose is a major energy substrate for the 
heart, which contributes to 30% of the heart’s overall energy through glucose oxidation 
during physiological states. Even with its ability to utilize other substrates such as fatty 
acids, lactate, ketone bodies, and amino acids, the heart utilizes glucose more than 
skeletal muscle, lung, or adipose tissue in order to maintain homeostasis (18, 19). 
Therefore, glucose uptake is crucial to healthy cardiac function. 




Diabetes is the most predominant risk factor for cardiovascular events in the United 
States (161), with heightened risk of myocardial infarction that contributes significantly 
to decreased life expectancy. It has been reported that patients with diabetes have a risk 
for MI comparable to that of recurrent MI in a nondiabetic patient. A Finnish population-
based study summarized their findings of the previous statement in that the 7-year 
incidence rates were 18.8% in subjects having MI without diabetes compared to 45% in 
subjects with MI and diabetes (162). Unfortunately, patients presenting diabetes at age 40 
have an approximate 8 year decreased life expectancy compared to nondiabetics (163). 
This prognosis worsens in T2DM patients that have experienced a myocardial infarction 
and, unfortunately, the underlying mechanisms of increased mortality associated to 
glucose levels are not understood. Interestingly, a human study of 52 patients with acute 
MI, ST segment elevation (corresponds to a period of ventricular depolarization, in 
which, elevation can forecast abnormalities in ventricular function), and hyperglycemia 
displayed that basal glucose levels are a suggestive predictor of left ventricular growth 
following acute MI (164). Even so, it has been reported that increased mortality within 30 
days of the MI was associated with increased hyperglycemia upon time of admission. 
Additionally, the former prognosis with the presence of diabetes was associated with 
poor outcomes over 3 years. From these data, it can be deduced that acute hyperglycemia 
observed in MI and T2DM should be considered as a risk factor in determining treatment 
avenues when a patient presents both MI and T2DM (165). Therefore, we will discuss the 
alterations in the metabolism of glucose during both diseased states. 
b. myocardial infarction  
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Apart from T2DM, the effect of MI on insulin-mediated glucose uptake in the heart 
remains unclear. Mouse model investigations using cardiac insulin receptor knockout 
mice revealed mitochondrial dysfunction and cardiomyopathy suggesting insulin 
resistance as a precursor of contractile dysfunction (166). Both long term (10 weeks) and 
short term (2 weeks) studies have been performed to investigate changes in cardiac 
metabolism and insulin sensitivity after MI. In a 10-week study, investigators reported 
decreased insulin-stimulated glucose uptake and reduced GLUT4 expression after MI 
(22). Yet, at the two weeks post-MI time point, there was no change in glucose uptake 
compared to control. Moreover, the lack of hypertrophy as well as insulin-stimulated total 
and phosphorylated Akt was unchanged between groups (20). Instead of highlighting 
contrasts between the long and short term effect of glucose uptake post-MI, these studies 
provide insights into the development of insulin resistance that may accrue with time post 
infarct. MicroPET imaging of glucose uptake after MI indicated a moderate to severe 
reduction in 18F-FDG uptake in the apex, apical anterior, and apical lateral segments as 
early as 48 hours post infarct. Interestingly, the mid anterolateral segment displayed 
marked decrease in 18F-FDG uptake initially that reversed after 2 weeks post MI and 
remained stable throughout the remainder of the study (21). A direct measurement of 
insulin-stimulated glucose uptake in chronically infarcted rat hearts after MI displayed 
significant decreases in the MI rats compared to control. Basal rates of glucose uptake 
remained consistent between all groups while insulin-stimulated glucose uptake was 
reduced by 42% in the MI model in parallel with a 28% decrease in GLUT4 expression 
within the same hearts (22). Therefore, it can be concluded that MI gives rise to insulin 
resistance leading to decreased glucose uptake via impairment of GLUT4 translocation. 
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c. diabetic cardiomyopathy 
The frequency of Type 2 diabetes mellitus (T2DM) has gradually increased over the last 
two decades. By 2030, this trend would lend close to half a billion people affected by this 
disease (167). Diabetic cardiomyopathy (DCM), now recognized as a complication of 
T2DM, is characterized by persistent hyperlipidemia, hyperglycemia, increased cardiac 
oxidative stress, myocardial fibrosis, inflammation, and disruption of Ca2+ handling along 
with mitochondrial dysfunction (168, 169). Clinically, DCM manifests itself in two 
phases; the first phase is characterized by abnormal myocardial energy metabolism, 
diastolic dysfunction and reduced LV strain to overt heart failure. The second phase is 
characterized by cardiomyocyte hypertrophy, myocardial fibrosis, and cardiomyocyte 
death, and whole-body insulin resistance (170-172). During DCM, cardiac dysfunction 
induced by pressure overload is associated with dysfunctional insulin signaling and 
decreased GLUT4 translocation (173). Furthermore, cardiac dysfunction is preceded by 
hyperinsulinemia and augmented Akt activation (173) as described in both animal (174) 
and human (175) patients with DCM. More specifically, hearts from obese and insulin-
resistant rodents displayed lower glucose oxidation rates and decreased cardiac efficiency 
(176, 177). Moreover, cardiomyocytes from high-fat-diet-fed (HFD-fed) mice display 
decreased GLUT4 expression and translocation in response to insulin as well as increased 
fatty acid (FA) oxidation rates (174). 
2.4 Therapies available for treatment of myocardial infarction 
Fibrinolytic therapy (FT) and Primary Percutaneous Coronary Intervention (P-PCI) are 
the two currently available options of reperfusion therapies for the treatment of 
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myocardial infarction. P-PCI executed in a timely manner is more effective than FT. 
Unfortunately, the downfall of P-PCI is that it is not universally available (178). Another 
liability of P-PCI is that it must be performed within 90 minutes upon arrival to the 
hospital (179). Patients receiving FT are also subjected to antiplatelet therapy 
encompassing the benefits of Aspirin and Clopidogrel, as well as the use of adjunctive 
anticoagulants such as Heparin, which reinforces fibrinolytic agents used for MI (180, 
181). Unfortunately, these therapies have many risks and adverse events, including 
recurrent ischemia, reinfarction, intracranial hemorrhage, and potential death. In addition,  
most patients have an increased risk to develop a thrombus after MI. Trials to increase 
epicardial coronary flow, prevent distal embolization, and reduce microvascular 
obstruction by a thrombectomy were not successful in reducing infarct size and 
improving left ventricular ejection fraction (182-184). Reperfusion therapy alongside 
adjunctive pharmacotherapy aids in the reestablishment of coronary flow, yet this 
restoration of coronary blood flow has been reported to cause further injury to cardiac 
myocytes (185). Reperfusion injury (185) is caused by oxidative stress (186, 187), 
calcium overload (188, 189), inflammation, and rapid restoration of pH (190). 
Understanding these mechanisms at a cellular level has led to renewed interest in 
designing treatment strategies targeting pathways, which mediate reperfusion injury. 
Research strategies focus on the cardioprotective effect mediated by multiple signaling 
pathways, although this is not well understood (191). Even with substantial 
enhancements in MI management, adverse event rates have not significantly decreased 
(192). 
2.4.1 Metabolic therapy for treatment of myocardial infarction 
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In spite of the formerly stated insufficient treatments, metabolic therapy has emerged as a 
promising field to determine the benefits of metabolic processes in treatment of patients 
with MI and HF. It has been proposed that optimizing energy substrate metabolism by 
inhibition of fatty acid β-oxidation, while increasing glucose oxidation will enhance ATP 
production and utilization efficiency, and therefore restore cardiac efficiency in the 
ischemic/reperfused failing hearts (193). A viable strategy to decrease the delivery of 
FFA to the myocardium would include therapeutically reducing circulating FFA 
concentrations therefore decreasing cardiac fatty acid β-oxidation in the post-ischemic 
period as well as in heart failure. It is known in heart failure that significant 
reduction/depletion of plasma FFA acutely and rapidly impairs cardiac efficiency, 
highlighting the necessity of fatty acids as an oxidative substrate in this setting (194). 
Understanding this, we can infer that careful evaluation of the degree to which circulating 
FFA concentration is decreased will be crucial in the determination of subsequent effects 
on cardiac efficiency and function.  
One such approach utilizes glucose–insulin–potassium (GIK) therapy which has been 
reported to increase the rates of glycolysis as well as decrease circulating concentrations 
of FFA (195, 196). Furthermore, the shift toward glucose utilization has been 
demonstrated to decrease infarct size (196) besides improving post-ischemic cardiac 
function (197). Several studies administering GIK therapy at reperfusion report its 
cardioprotective benefits (196, 198, 199). Yet, one must take into account that the level of 
circulating FFA supplied to the myocardium directly influences the effect of insulin 
(200). Furthermore, unbalanced stimulation of glycolysis relative to glucose oxidation is 
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known to uncouple the two processes, increase intracellular acidosis (201), and may 
diminish the cardioprotective effects of insulin (200).  
Several fatty acid β-oxidation inhibitors have been developed and proven effective 
against ischemic heart disease and heart failure. Carnitine palmitoyltransferase I is the 
rate-limiting enzyme mediating mitochondrial fatty acid uptake, making an attractive 
target for the inhibition of myocardial fatty acid β-oxidation. A number of carnitine 
palmitoyltransferase I  inhibitors have been developed, including etomoxir (202) and 
perhexiline (203), both demonstrating anti-ischemic effects as well as beneficial effects in 
the treatment of heart failure. Trimetazidine is a partial fatty acid β-oxidation inhibitor 
that competitively inhibits long chain 3-ketoacyl-CoA thiolase (204). Results from 
clinical studies have confirmed the effectiveness of trimetazidine as an anti-ischemic 
agent (205).  Metabolic therapy, though currently incomplete, is a promising avenue for 
the treatment of myocardial infarction. We hypothesize that NRG is a novel metabolic 








3.1 Ventricular myocyte isolation 
Animals were deeply anesthetized by 1mL pentobarbital sodium injection or 3-5% 
isoflurane, and the heart and lungs rapidly excised. The heart was perfused in a retrograde 
manner, using a Langendorff apparatus with Tyrode buffer (37°C, pH = 7.35 and 
oxygenated with 95% O2 and 5% CO2), which contained (in mM): NaCl (135), KCl (5.4), 
MgCl2 (1), NaH2PO4 (0.33), Hepes (10), glucose (10), and CaCl2 (1). This initial 
perfusion was followed by a perfusion with Tyrode buffer free of CaCl2. Subsequently, 
collagenase (type II, 1 mg/ml, Worthington Biochemical) was added to the calcium-free 
Tyrode buffer and recirculated for the rest of the perfusion period. When the heart was 
softened the ventricles were minced and the cells were subsequently washed in Tyrode 
solution containing CaCl2 (0.125 mM). Only rod-shaped cells with sharp margins and 
clear striations were included in the study. All recordings were made within 5 hours of 
isolation (206-208). All the procedures of this study were approved by the Oklahoma 
State University Institutional Animal Care and Use Committee (ACUP# VM 12-3).
34 
 
3.2 Glucose uptake assay 
A nonradioactive assay was performed using a fluorescent D-analog, 1-N-7-(nitrobenz-2-
oxa-1,3-diazol-4-yl)amino-2-deoxy-D-gluocose (2-NBDG) in isolated fresh cardiac 
myocytes and a glucose uptake cell-based assay kit, following manufacture’s 
recommendation (Cayman Chemical, MI, USA). The cells were plated on a 96-well plate 
at a density of 5,000 cells/well in glucose-free Tyrode buffer and incubated with/without 
100 ng/ml GGF2 or 0.0349 mM insulin for at least 30 minutes. 100 uM 2-NBDG was 
then administrated to each well. After 10 minutes incubation, cells were washed with 
PBS (200uL/well) twice, and fluorescence was measured using a microplate reader at 
excitation/emission wavelengths of 535/758 nM. 
3.3 Western immunoblotting 
Following a 1 hour incubation with or without 300 nM afatinib (Selleck Chemicals, Cat 
No.S1011), cells were incubated for 1 hour with 100 ng/ml GGF2 (ACORDA 
Therapeutics), 0.5 mM CaCl2 (Sigma-Aldrich), 100 nM AICAR (Sigma-Aldrich, 
A9978), or 0.0349 mM Insulin (Thermo-Fisher). Cells were then lysed with 1:500 RIPA 
(Thermo-Fisher) and Protease Inhibitor Cocktail (Sigma-Aldrich, P8340) and the total 
lysate was stored in -80˚C. The bicinchoninic acid assay (BCA assay) was 
the biochemical assay used to determine the total concentration of protein in solution. 
The total protein concentration is exhibited by a color change of the sample solution from 
green to purple in proportion to protein concentration, which can then be measured 
using colorimetric techniques. Equal amounts of protein (5–20μg) were resolved in an 8–
12% SDS-polyacrylamide gel and electrophoretically transferred (Bio-Rad) to a 
polyvinyl-idine fluoride membrane (Bio-Rad), as previously described [22; 24–
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27; 29; 30]. After blocking (1–5% non-fat dry milk or 2% goat serum albumin), 
membranes were incubated with optimally diluted primary antibodies overnight 
(polyclonal rabbit anti-human GLUT4, 1:750, AbD Serotec 4670–1704; monoclonal 
rabbit anti-mouse total Akt, 1:1000, Cell Signaling 4061; monoclonal rabbit anti-human 
phosphorylated Akt s473, 1:1000, Cell Signaling 4060; monoclonal rabbit anti-mouse 
phosphorylated Akt Th308, 1:1000, Cell Signaling 2965; monoclonal rabbit anti-human 
total AS160, 1:1000, Cell Signaling 2670 and polyclonal rabbit anti-human 
phosphorylated AS160, 1:1000, Cell Signaling 9611; polyclonal rabbit anti-human PDK-
1, 1:1000, Cell Signaling 3062; Monoclonal rabbit anti-human phosphorylated PDK-1 
S241, 1:1000, Cell Signaling 3438; Monoclonal Rabbit IgG anti-human PKC zeta Th410, 
1:500, Cell Signaling 2060; polyclonal rabbit anti-human PKC zeta, 1:1000, Cell 
Signaling 9372); washed for 10 minutes with TPBS (twice), 5 minutes with PBS, 
followed by a 1 hour incubation of appropriate secondary antibodies conjugated to 
horseradish peroxidase (for total and phosphorylated Akt, PKC, PDK-1 and AS160, Cell 
Signaling 7074, 1:2000, polyclonal goat anti-rabbit; for GLUT4, GE Healthcare 
NA934V, polyclonal donkey anti-rabbit). Membranes were again washed for 10 minutes 
with TPBS (twice), and 5 minutes with PBS. Primary antibodies were chosen based on 
their 100% sequence homology with the protein of interest in rodents, and validated 
against a positive control (i.e., tissue, peptide). Antibody-bound transporter proteins were 
quantified by enhanced chemiluminescence reaction (KPL) and autoradiography. Band 
density and molecular weight were quantified using GelPro Analyzer (Media 
Cybernetics). The data was expressed relative to appropriate controls. Equal protein 
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loading was confirmed by reprobing each membrane with Calsequestrin monoclonal IgG 
(Thermo-Scientific PA1-903, 1:2500, polyclonal rabbit anti-rat). 
3.4 Quantification of GLUT translocation to the cell surface 
Following a 1 hour incubation with or without 300 nM afatinib (Selleck Chemicals, Cat 
No.S1011), cells were incubated for 1 hour with 100 ng/ml GGF2 (ACORDA 
Therapeutics), 0.5 mM CaCl2 (Sigma-Aldrich), 100 nM AICAR (Sigma-Aldrich, A9978), 
or 0.0349 mM Insulin (Thermo-Fisher), and were photolabeled with the cell-surface-
impermeant biotinylated bis-glucose photolabeling reagent (bio-LC-ATB-BGPA, 300 
μM, Toronto Research Chemicals, ON, Canada), of which the hexose group interacts 
specifically with the extracellular binding site of GLUTs. The photolabeled reagent was 
cross-linked to cell surface GLUTs using a Rayonet photochemical reactor (340 nM, 
Southern New England UV), as previously described (209-211). Cells were then lysed 
with 1:500 RIPA (Thermo-Fisher) and Protease Inhibitor Cocktail (Sigma-Aldrich, 
P8340) and the total lysate was stored in -80˚C. Recovery of photolabeled (cell surface) 
GLUTs from total cardiac membranes (200μg) was achieved using streptavidin isolation 
(bound to 6% agarose beads) to facilitate separation of non-cell surface GLUTs 
("unlabeled" or intracellular fraction that remains in the supernatant) from cell surface 
GLUTs ("labeled" or sarcolemmal fraction). The labeled GLUTs were then dissociated 
from the streptavidin by boiling in Laemmli buffer for 60 min prior to SDS-PAGE and 
subsequent immunoblotting with GLUT antibody. The Laemmli buffer is described as 
follows based upon its components. The 2-mercaptoethanol reduces the intra and inter-
molecular disulfide bonds. The SDS detergent denatures the proteins and subunits and 
gives each an overall negative charge so that each will separate based on size. The 
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bromophenol blue serves as a dye front that runs ahead of the proteins and also serves to 
make it easier to see the sample during loading. The glycerol increases the density of the 
sample so that it will layer in the sample well. Proteins from the labeled fraction were 
quantified by densitometry relative to the positive control, as previously described (209, 
210, 212). 
3.5 Statistical analysis 
Differences between means were assessed using Student’s t-tests. Repeated measured 
One way ANOVA was performed with Student Newman Keuls post-hoc test for in 
vitro measurements, as appropriate. If not normally distributed, the data was analyzed 
with a Mann-Whitney or Friedman test. Statistical significance was defined as P<0.05. 







4.1 In vitro GGF2 treatment increases glucose uptake 
To determine whether acute in vitro GGF2 treatment modulates glucose uptake in healthy 
cardiac myocytes, we isolated cardiac myocytes via Langendorff perfusion and subjected 
them to incremental doses of GGF2 or insulin for 30 minutes prior to incubation with 2-
NBDG, a fluorescently labeled glucose analog, for 30 minutes. Glucose uptake was 
measured by fluorescent detection via microplate reader. Similar to insulin, GGF2 
treatment, both 1 ng/ml and 100 ng/ml resulted in increased glucose uptake, by 39% and 
49%, respectively, compared to basal (P<0.05 Figure 6A). It is worthwhile to note that 
incubation with 10ng/ml resulted in glucose uptake similar to insulin, however, due to the 
variability within the samples the changes were not significant. Furthermore, Western 
blotting of total GLUT4 (Figure 6B) demonstrated a significant increase of total GLUT4 





Figure 6A: Glial growth factor 2 (GGF2) stimulates glucose uptake in isolated 
cardiac myocytes. Mean ± SE of glucose uptake; values normalized to basal 
(n=6/group); # P<0.05 relative to basal. Methods: A nonradioactive assay was performed 
using 2-NDBG glucose uptake assay. Isolated cardiac myocytes were incubated 
with/without 100 ng/ml GGF2 or 0.0349 mM insulin for at least 30 minutes prior to 10 
minutes incubation with 2-NDBG. Fluorescence was measured using a microplate reader 
at excitation/emission wavelengths of 535/758 nM. B: GGF2 increases total GLUT4 
expression. Top panel: representative Western blot. Bottom panel: Mean ± SE of protein 
expression (values expressed relative to basal; n=11-15/group); # P<0.05 vs. basal 
(Mann-Whitney rank sum test). Methods: Total lysate of isolated rat ventricular myocytes 
incubated with 0.0349 mM insulin or 1 ng/ml, 10 ng/ml, or 100 ng/ml GGF2; 
Calsequestrin (CLSQ) was used as a loading control.  
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Figure 8: Afatinib covalently binds to cysteine number 
797 of the epidermal growth factor receptor (EGFR) 
via a Michael addition (IC50 = 0.5 nM) (4). 
4.1.2 In vitro GGF2 treatment increases GLUT4 translocation 
We have previously demonstrated in our lab that GLUT4 translocation was significantly 
increased in cells treated with insulin (97%, P<0.02) for one hour compared to basal 
treatment (212); therefore, we used insulin as a positive control. To measure GLUT4 
trafficking, the rate-limiting in glucose uptake, we performed the state-of-the-art 
technique biotinylation photolabeled assay that specifically quantifies cell membrane 
GLUTs (Figure 7A and B). We demonstrated significant increases of GLUT4 
translocation in GGF2-treated myocytes at both 1 ng/ml and 100 ng/ml (by 99% and 
184%, respectively, P<0.05) 
compared to basal. Afatinib is 
a protein kinase inhibitor that also 
irreversibly  inhibits ErbB2 
and -4 by covalently binding 
to cysteine number 797 of 
the ErbB via a Michael addition. Because afatinib had not been tested in cardiac 
myocytes, we incubated the myocytes with ascending concentrations of 300- and 500 
nM, as suggested by research in other tissue types (213). GGF2-stimulated GLUT4 
translocation to the cell membrane was blunted by the addition of 300- and 500 nM 
afatinib, the ErbB2 and -4 inhibitor, prior to incubation with GGF2 (Figure 7B). These 
findings suggest that GGF2-modulated glucose uptake via GLUT4 translocation and that 
















Figure 7A: Glial growth factor 2 (GGF2) stimulates GLUT4 trafficking to the 
cardiac cell surface. Top panels: representative Western blot. Bottom Panels: Mean 
± SE of cell surface GLUT4 protein content; values normalized to basal ventricle (n=3-
8/group); # P<0.05 vs. basal (t-test). Methods: Cell membrane fraction of isolated rat 
ventricular myocytes incubated with or without 0.0349 mM insulin, 1 ng/ml, 10 ng/ml, or 
100 ng/ml GGF2 for one hour. Cell surface GLUTs were measured using biotinylated 
photolabeling technique in isolated rat ventricular myocytes. L: Labeled (cell surface 
fraction); UL: Unlabeled (intracellular fraction). B: Afatinib attenuates GGF2 
stimulated translocation of GLUT4 in ventricular myocytes. Top panels: 
representative Western blot. Bottom Panels: Mean ± SE of cell surface protein expression 
(values expressed relative to basal); # P<0.05 vs. basal; * P<0.05 vs GGF2. S: Afatinib 
from Selleck Chemicals; LC: Afatinib from LC Laboratories. Methods: Cell membrane 
fraction of isolated rat ventricular myocytes incubated with or without ErbB blocking 
antibodies (Afatinib, 300 nM and 500 nM from Selleck Chemicals or LC Laboratories) 
for 1 hour prior to incubation with or without insulin (0.0349 mM) or GGF2 (100 ng/ml). 
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4.2 In vitro GGF2 treatment stimulates glucose uptake via PI3K-dependent 
pathway 
4.2.1 GGF2 increases phosphorylation of PDK-1 
It has been proposed that neuregulin-1 regulates glucose metabolism in both skeletal and 
cardiac muscle via activation of downstream effectors including P13K and Akt (6, 8, 
159). Yet, whether GGF2 increases glucose uptake via a PI3K-dependent pathway is 
unknown. Therefore, we hypothesized that there will be increased phosphorylation of 
PI3K’s downstream effector, PDK-1 in both insulin- and GGF2-treated cardiac myocytes. 
Insulin and GGF2 both elicited increases in phosphorylated PDK-1 compared to basal 
(91% and 206%, respectively, P<0.05, Figure 9A). No increase in total expression of 
PDK-1 after one hour treatment of GGF2 was observed, suggesting that this protein’s 










Figure 9A: Insulin and GGF2 stimulates PDK-1 phosphorylation in ventricular 
myocytes. Top panel: representative Western blot. Bottom panel:  Mean ± SE of protein 
expression (values expressed relative to basal; n=4-5/group); # P<0.05 vs. basal. 
Methods: Total lysate of isolated rat ventricular myocytes were incubated with 0.0349 
mM insulin or 100 ng/ml GGF2; Calsequestrin (CLSQ) was used as a loading control. B: 
Total PDK-1 protein expression upon insulin and GGF2 treatment of ventricular 
myocytes. Top panels: representative Western blot. Bottom panels: Mean ± SE of protein 
expression (values expressed relative to basal; n=17/group); # P<0.05 vs. basal. Methods: 
Total lysate of isolated rat ventricular myocytes were incubated with 0.0349 mM insulin 
or 100 ng/ml GGF2; Calsequestrin (CLSQ) was used as a loading control. 
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4.2.2 GGF2 increases Akt phosphorylation and expression 
PDK-1, once activated, targets the phosphorylation of Akt, a protein well understood to 
play a key role in glucose uptake in insulin sensitive tissues (110). It is well documented 
that insulin increases Akt phosphorylation at both th-308 and ser-473 sites; therefore, our 
observations of phosphorylated thr-308 and ser-473 in response to insulin (57% and 
524%, respectively, P<0.05) were consistent with previous literature (212). In cells 
incubated with GGF2 for 1 hour, p-thr308-Akt displayed a significant increase of 75% 
(P=0.029) compared to basal (Figure 10A). Furthermore, we observed a 139% (P=0.01) 
increase in p-ser473-Akt upon GGF2 treatment (Figure 10B). Therefore, to determine if 
this response was a direct response of GGF2’s activation of its ErbB2 and -4 receptors, 
we blocked the ErbB2 and -4 receptors with afatinib. As expected, both p-thr308 and p-
ser473 phosphorylation returned to their basal level upon blockage of the ErbB2 and -4 
receptors (Figure 10A &B). Lastly, a similar response was demonstrated in total Akt 
expression for both insulin and GGF2 compared to basal (91% and 95%, respectively, 
P<0.05), although blocking the ErbB2 and -4 receptors with afatinib prior to treatment 













Figure 10: Analysis of the downstream insulin signaling pathways in the healthy 
myocardium. Afatinib attenuates GGF2 stimulation of Akt phosphorylation at A) 
Th308 and B) s473 sites in ventricular myocytes. Top panels: representative Western 
blot. Bottom panels: Mean ± SE of protein expression (values expressed relative to basal; 
n=3-4/group); # P<0.05 vs. basal; * P<0.05 vs GGF2 Methods: Total lysate of isolated rat 
ventricular myocytes incubated with insulin (0.0349 mM), ErbB blocking antibodies 
(Afatinib, 300 nM and 500 nM) or GGF2 (100 ng/ml); Calsequestrin (CLSQ) was used as 
a loading control.  Bottom panels: Mean ± SE of protein expression (values expressed 
relative to basal; n=3-4/group); # P<0.05 vs. basal; * P<0.05 vs GGF2. C) Total Akt 
protein expression upon insulin, GGF2 and GGF2+Afatinib treatment of ventricular 
myocytes. Top panels: representative Western blot. Bottom panels: Mean ± SE of protein 
expression (values expressed relative to basal; n=4-5/group); # P<0.05 vs. basal. 
Methods: Total lysate of isolated rat ventricular myocytes were incubated with 0.0349 




4.2.3 GGF2 stimulates AS160 phosphorylation and expression 
As its name suggests, Akt substrate at 160kD, commonly known as AS160, is a direct 
target of Akt (116). Upon phosphorylation of AS160, GLUT4 vesicles are released to the 
cell membrane. Therefore, to confirm that GGF2 does, in fact, activate GLUT4 via an 
AS160-dependent mechanisms, we quantified total and phosphorylated AS160 after cells 
were incubated with GGF2 or insulin for 1 hour (Figure 11A). Increased AS160 
phosphorylation was observed after insulin and GGF2 stimulation (69% and 72%, 
respectively, P<0.05). Furthermore, insulin and GGF2 treatment in adult cardiac 
myocytes induced a 96% and 99% increase, respectively, in total AS160 compared to 
basal (P<0.05%) (Figure 11B). These data suggest that similar to insulin, acute in vitro 
GGF2 treatment activates the downstream effectors of the PI3K pathway, including 








Figure 11: Analysis of the downstream insulin signaling pathways in the healthy 
myocardium. A) Insulin and GGF2 stimulates AS160 phosphorylation in ventricular 
myocytes. Top panel: representative Western blot. Bottom panel: Mean ± SE of protein 
expression (values expressed relative to basal; n=14-15/group); # P<0.05 vs. basal. 
Methods: Total lysate of isolated rat ventricular myocytes were incubated with 0.0349 
mM insulin or 100 ng/ml GGF2; Calsequestrin (CLSQ) was used as a loading control.  B) 
Total AS160 protein expression upon insulin and GGF2 treatment of ventricular 
myocytes. Top panels: representative Western blot. Bottom panels: Mean ± SE of protein 
expression (values expressed relative to basal; n=17/group); # P<0.05 vs. basal. Methods: 
Total lysate of isolated rat ventricular myocytes were incubated with 0.0349 mM insulin 
or 100 ng/ml GGF2; Calsequestrin (CLSQ) was used as a loading control. 
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4.2.4 GGF2 increases phosphorylation of PKCζ in adult cardiac myocytes 
To determine if GGF2 activates glucose uptake independently of Akt, we explored an 
alternative target of PDK-1.  In the presence of insulin, the downstream target PDK-1 is 
known to activate PKCζ-induced GLUT4 translocation, independently of Akt and AS160 
(123). When compared to basal conditions, our data indicated increases in p-PKCζ 
expression in the presence of insulin and, as well as, GGF2 (158% and 100%, 
respectively, P<0.05, Figure 12A). Total expression of PKCζ was unchanged compared 





Figure 12: Analysis of the downstream insulin signaling pathways in the healthy 
myocardium. A) Insulin and GGF2 stimulates phosphorylation of PKC zeta at 
Th410 site in ventricular myocytes. Top panels: representative Western blot. Bottom 
panels: Mean ± SE of protein expression (values expressed relative to basal; n=9/group); 
# P<0.05 vs. basal. Methods: Total lysate of isolated rat ventricular myocytes were 
incubated with 0.0349 mM insulin or 100 ng/ml GGF2; Calsequestrin (CLSQ) was used 
as a loading control.  B) Total PKC protein expression upon insulin and GGF2 
treatment of ventricular myocytes. Top panels: representative Western blot. Bottom 
panels: Mean ± SE of protein expression (values expressed relative to basal; n=7/group). 
Methods: Total lysate of isolated rat ventricular myocytes were incubated with 0.0349 




4.3 Calcium activated GLUT4 translocation is dependent on ErbB2 and -4 
It has been reported that the inhibition of ErbB2 receptors use for the treatment of lung 
cancer resulted in severe cardiac complications (214). It is also known that calcium not 
only plays a major role in cardiac contraction but also glucose uptake (148), although the 
mechanisms are not fully understood. Therefore, we hypothesized that calcium activates 
GLUT4 translocation through an ErbB2 and -4 signaling pathway. We incubated cardiac 
ventricular myocytes with/or without ErbB2 and -4 inhibitor, afatinib, for one hour prior 
to incubation with calcium. Calcium stimulation yielded a 511% (P<0.001) increase in 
GLUT4 translocation compared to basal levels. Upon ErbB2 and -4 blockage, we 
observed a 408% (P<0.05) decrease in cell surface GLUT4 in contrast to calcium alone 
(Figure 13). Blocking ErbB2 and -4 did not completely eradicate calcium-stimulated 
glucose uptake. This data suggested that calcium-stimulated glucose uptake is mediated 



















Figure 13: Analysis of the downstream calcium signaling pathway in the healthy 
myocardium. Afatinib attenuates calcium stimulated translocation of GLUT4 in 
ventricular myocytes. Top panels: representative Western blot. Mean ± SE of protein 
expression (values expressed relative to basal; n=4-6/group); # P<0.05 vs. basal; * 
P<0.05 vs. calcium. Methods: Cell surface GLUTs were measured using biotinylated 
photolabeling technique on isolated rat ventricular myocytes incubated with and without 
300 nM Afatinib prior to incubation with 100 ng/ml GGF2 or 0.5 mM CaCl2. L: Labeled 








Although neuregulin 1-β and its ErbB2 and -4 receptors are essential in the development 
and maintenance of the heart, little is known about the mechanisms by which it promotes 
cell survival and differentiation. In this study, we demonstrated that NRG1β isoform, 
glial growth factor 2 (GGF2), stimulates GLUT4 translocation, and thus increases 
glucose uptake in healthy adult rat cardiac myocytes via PDK-1-, Akt-, AS160-, and 
PKCζ-dependent mechanisms. Furthermore, we reported that calcium-mediated glucose 
uptake in isolated cardiomyocytes is dependent on ErbB2 and -4 receptors. These 
findings highlighted some novel mechanisms of action of GGF2, which warrant further 
investigation in patients with heart failure. 
5.1 GGF2 increases glucose uptake in adult cardiac myocytes 
Neuregulin-1β and its ErbB 2/4 receptor have vital roles in the development and 
maintenance of the heart (27). Being within the epidermal growth factor family, NRG-1 
action on cells promotes proliferation, differentiation, and survival (27-30). In this study, 
we demonstrated that GGF2 treatment modulates glucose uptake in healthy adult cardiac 
myocytes via a PDK-1, Akt, AS160, and PKCζ-dependent mechanism. Studies done in 
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both L6E9 myotubes (25) and soleus muscle (159) support the implication of a 
neuregulin-stimulated PI3K-dependent mechanism facilitating glucose uptake. In a study 
using L6E9 myotubes treated with neuregulin, Dr. Canto’s group indicated an increased 
activation of the PDK-1 pathway via the ErbB3 receptor (25). Although, ErbB3 is not 
reported to be expressed in adult cardiac myocytes, we demonstrated similar responses in 
the PDK-1 pathway activation when treated with neuregulin. Furthermore, Canto’s lab 
reported neuregulin-stimulated glucose transport was additive to insulin, suggesting this 
as an alternative mechanism to insulin-stimulated glucose uptake (25). Recently Dr. 
Pentassuglia and colleagues demonstrated that NRG1-β enhanced glucose uptake in 
neonatal cardiomyocytes as efficiently as insulin-like growth factor-1 and insulin (215). 
The metabolism of neonatal cardiomyocytes is different than adult myocytes and do not 
reflect the physiological process in the heart. For instance, shortly after birth, cardiac 
myocytes switch from predominant expression of glucose transporter GLUT1 to the 
insulin-sensitive isoform GLUT4. This switch coincides with the development of insulin 
sensitivity and shift from a straight carbohydrate to a mixed fat/carbohydrate diet (216). 
Furthermore, our study utilized GGF2 over rhNRG-1 as studies have shown that single 
intravenous dose of GGF2 has parallel efficacy to the EGF-domain only fragment of 
rhNRG-1 which was given as daily intravenous infusions over 10 days (11, 12). 
5.1.1 GGF2 increases GLUT4 translocation in adult cardiac myocytes 
Glucose uptake, the rate-limiting step in whole-body glucose homeostasis, is regulated by 
a family of specialized proteins, called the GLUTs.  GLUT4 is the major isoform 
expressed in myocytes and is translocated from an intracellular pool to the cell membrane 
during insulin-mediated glucose uptake. Under basal conditions, GLUT4 is primarily 
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located within multiple intracellular compartments such that only 2-5% is observed at the 
plasma membrane (89-93). Many techniques have been developed to study metabolism in 
the myocardium, yet, the quantification of cell surface GLUTs, which is necessary to 
reveal the molecular mechanisms of glucose transport regulation, has proved very 
challenging in murine models. As an example, it is difficult to apply conventional 
membrane fractionation techniques to rodents due to the size limitation of their hearts. 
Furthermore, immunohistochemistry and immunofluorescent techniques cannot 
differentiate the inactive GLUTs from the active GLUTs. Additionally, neonatal cardiac 
myocyte studies, for which GLUT4 is only a minor isoform, is not physiologically 
relevant to intact adult myocytes. Therefore, we measured GLUT4 trafficking by the 
state-of-the-art technique biotinylation photolabeled assay that quantifies cell membrane 
GLUTs. In this way, we are able to overcome a substantial obstacle in metabolism 
research, in that we directly quantified the activation and translocation of the GLUT4. 
Our lab has further validated this technique in quantifying GLUTs in the insulin 
stimulated GLUT4, -8 translocation as well as insulin-independent GLUT12 in the rat 
ventricular myocytes as well as intact mouse ventricle and atria (23, 212, 217). Our 
results suggest that short-term GGF2 treatment stimulates GLUT4 translocation in 
cardiomyocytes to the same extent as insulin. Similarly, Dr. Suarez and colleagues 
demonstrated a 43% increase in GLUT4 abundance within plasma membrane fractions of 
skeletal myocytes. Furthermore, his research demonstrated that GLUT1 and GLUT3 
translocate to the same extent in response to the treatment of skeletal muscle with 
neuregulin (159). However, to our knowledge, this is the first report on the effect of acute 
in vitro GGF2 treatment on GLUT4 translocation in cardiomyocytes. 
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These cardioprotective mechanisms are initiated upon NRG-1 binding its tyrosine kinase 
receptors (ErbB2, ErbB3, and ErbB4), triggering phosphorylation and the downstream 
cascade of effectors (38). In alignment with previous studies on incubated soleus muscle 
(24) and neonatal cardiomyocytes (215), we demonstrated that inhibition of ErbB2 and 
ErbB4 impaired neuregulin-induced glucose transport. We further confirmed that GGF2 
action on GLUT4 translocation in cardiac myocytes was significantly blunted by the 
irreversible ErbB 2/4 inhibitor, afatinib. By isolating the cardiac myocytes from whole 
tissue, we eliminated the possibility of endogenous receptor activation by endothelial 
cells producing NRG to bind the ErbB receptors in the cardiac myocytes. Therefore, 
activation of the ErbB receptors were due to the addition of exogenous GGF2.  
5.2 GGF2 stimulates glucose uptake via an Akt-dependent pathway in adult cardiac 
myocytes 
 It has been well elucidated 
that ErbB2 and ErbB4 
activation initiates PI3K 
signaling cascades in 
different tissue types (36, 
218). Similarly, our results 
indicated an increase in PDK-
1 phosphorylation, a 
downstream target of PI3K, 
in response to GGF2 
Figure 14: The downstream GGF2 signaling 
pathway. The above schematic outlines a portion of 
the downstream GGF2-signaling pathway. 
Abbreviations are used as follows: PI3K = 
Phosphoinositide 3-kinase, PDK1= Phosphoinositide-
dependent kinase-1, PKC = Protein kinase C, Akt2 = 
Protein kinase B isoform 2, AS160 = Akt substrate at 
160 kD, GLUT4 = Glucose transporter isoform 4 
(artistic credit to Allison Campolo). 
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treatment in adult cardiomyocytes. In L6E9 myotubes, PDK-1 is also demonstrated to be 
an essential downstream target of PI3K, in the induction of glucose transport by 
neuregulin stimulation (25). The marked increase in p-PDK-1 leads us to infer that it is 
highly sensitive to GGF2 similar to the traditionally accepted activation by insulin (104). 
Furthermore, our results showed increase in phosphorylation of Akt, a downstream target 
of PDK1 (104), following GGF2 treatment. It is well documented that insulin stimulation 
increases Akt phosphorylation at both th-308 and ser-473 sites in cardiomyocytes; 
therefore, our observations of phosphorylated th-308 and ser-473 in response to insulin 
were in agreement with previous literature (212). Similarly, NRG-1 is known to activate 
Akt phosphorylation in neonatal myocytes, L6E9 myotubes, and soleus muscle (25) 
(215). In the current study, inhibition of the ErbB 2/4 receptors by afatinib diminished 
neuregulin-stimulated Akt phosphorylation at both the serine and threonine sites. These 
findings suggest that Akt is an essential downstream target of ErbB2/4 phosphorylation in 
the stimulation of glucose uptake. In addition, upon GGF2 stimulation, we observed a 
significant increase in the activation AS160, the downstream effector of Akt. Taken 
together, these data indicated that GGF2 treatment increases glucose uptake in 
cardiomyocytes independent of insulin via the PI3K/AS160 pathway (Figure 13, artistic 
credit to Allison Campolo). 
A lesser known pathway, but just as necessary, is the PDK1 activation of PKCζ in the 
stimulation of glucose uptake. An insulin stimulus is known to rapidly increase PKC-ζ 
activity in adipocytes (122), L6 myotubes (123), and 32D cells (125) via PI3K-dependent 
stimulation (123-125). In the current study, we identified an alternative pathway for 
glucose uptake in which acute GGF2 treatment significantly increases activation of PKCζ 
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in cardiomyocytes, to the same extent as insulin stimulation. This is in contrast with 
previous reports in which neuregulin had a stronger maximal effect on PKC than insulin 
in L6E9 myotubes.(25). From these data we conclude that GGF2 increases glucose 
uptake in a PKCζ-dependent mechanism in cardiac myocytes, but to a lesser extent than 
what is observed in skeletal muscle. 
5.3 Calcium activated GLUT4 translocation is dependent on ErbB2 and -4 in adult 
cardiac myocytes 
In striated muscle, GLUT4 translocation is activated through the signaling pathways of 
both contraction and insulin, which act independently of each other to induce glucose 
uptake. Notably, during insulin resistance, there is no alterations on the effects of 
contraction-mediated glucose uptake, suggesting that contraction and insulin utilize 
independent mechanisms to stimulate glucose uptake (219, 220). Although it is 
previously described that increases in intracellular Ca2+, even at minimal concentrations 
that do not excite muscle contraction, stimulates GLUT4 translocation in skeletal muscle 
(221) and adipose (222), less is known about Ca2+-mediated glucose transport in the 
heart. Previously our lab provided insights into this mechanism using a transgenic mouse 
model with cardiac-specific upregulation the sarcoplasmic reticulum Ca2+-ATPase 
(SERCA) pump. We demonstrated that the SERCA pump, the only mechanism to 
maintain SR/ER Ca2+ stores within cardiac myocytes, regulated cardiac glucose 
homeostasis via an insulin-independent pathway (23). 
Ex vivo electrically-stimulated muscle contractions in both slow- and fast-twitch muscles 
activated both ErbB2 and ErbB4 receptors via a ligand-dependent manner. Both slow- 
and fast-twitch muscles upon electrical stimulation released NRG molecules into the 
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media (24). Furthermore, blockage of ErbB4 receptor impaired the contraction-induced 
glucose uptake observed in these tissues. In a separate experiment by Dr. Canto, caffeine-
induced calcium release from the sarcoplasmic reticulum increased ErbB 2/4 
phosphorylation (24). This receptor activation was, again, blocked upon treatment with 
ryanodine receptor blocker, dantrolene, which inhibits calcium recycling within the cell 
(24). In the present study, we incubated isolated cardiac myocytes with physiological 
concentrations of calcium. As our results indicated, upon ErbB 2/4 blockage by afatinib, 
a marked reduction in calcium-initiated GLUT4 translocation was observed. However, 
blockage of ErbB 2/4 did not completely inhibit calcium-activated GLUT4. Therefore, 
one could assume that calcium activates alternative pathways, including AMPK or 
CaMK. In accordance with previous literature reporting a marked increase in cardiac 
glucose uptake compared to insulin-stimulated (24). Thus, to our knowledge, this is the 
first report that calcium-stimulated GLUT4 translocation is primarily mediated by ErbB 
2/4 receptors in cardiac myocytes. With our findings we conclude that calcium-stimulated 







Using a cell surface biotinylation assay, we demonstrated that the major GLUT isoform, 
GLUT4, is a GGF2-sensitive glucose transporter. Our data further suggested that GLUT 
translocation to the cell surface, which regulated glucose uptake, is modulated by the 
downstream PI3K-dependent pathway via Akt and AS160 phosphorylation as well as 
PKCζ. We demonstrated that inhibiting the ErbB2 and -4 receptors impairs the GGF2-
stimulated trafficking of GLUT-4. Furthermore, we determined that inhibition of the 
ErbB2 and -4 receptors pointedly diminishes calcium-induced glucose transport. 
 In spite of the currently insufficient treatments for MI, metabolic therapy is emerging as 
a promising field utilizing the benefits of metabolic processes for treatment of patients 
with MI and HF. Indeed, increased glucose uptake has been shown to be cardio-
protective during myocardial infarction (193). Therefore, the enhancement of glucose 
transport reported by this study give further insights into the cardioprotective role of 
GGF2, alongside its ErbB receptors, in patients with myocardial infarction. Therefore, 
better understanding of the regulation of GGF2-stimulated glucose transport may lead to 
its use as a novel therapeutic target for the treatment of patients who have suffered a 
myocardial infarction.  
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Table: Selected proposed functions of NRGs
Table 1: Selected proposed functions of NRGs. This list is not intended to be 
comprehensive, and further investigation will be required to confirm the physiological 
significance of many of the proposed roles. Some proposed functions have been 
inferred principally from the effects of exogenously supplied recombinant NRG1, 
ErbB blockade, or ErbB knock-out; in these cases the physiological signal may 
actually be NRG2, 3, or 4 or another ErbB ligand. Caveat emptor. Functions proposed 
solely on the basis of mRNA/protein expression data are not included. Reviews have 
been cited for proposed functions of NRG1s in Schwann cell and neuromuscular 
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